As High-Priced Immuno- & Gene Therapies Multiply, Who Pays and How?
Costing hundreds of thousands, even millions of USD per individual, a handful of immuno- and gene therapies have been developed to-date. But in fact it’s no longer correct to talk of just “a handful” – usage expansion is already well underway and set to increase medium term.
The HIV/AIDS Epidemic – What’s New? Pre-exposure Prophylaxis (Part II)
While there is yet no HIV vaccine, a small blue pill can prevent HIV transmission. RGA explores the power of PrEP (pre-exposure prophylaxis) as an effective prevention strategy, as well as potential risks, protocols, and barriers to greater use.
Insuring More Cancer Survivors Through Inclusive Underwriting
The improvement in cancer survival rates has led to a growing life insurance need for cancer survivors worldwide. To mark World Cancer Day, Manuel Plisson, SCOR Global Life Head of Inclusive Underwriting & Medical Expertise, discusses an inclusive rating approach that could help address this protection gap.
Have you noticed that the word invasive is being bandied about more and more often in underwriting-related articles and commentaries published online and in various industry publications? This is mainly being done by those advocating radical changes in underwriting practices.
The purpose of this paper is to discuss the insurability implications of low normal/ below normal ALT in the elderly… in the hope that insurers will consider adding appropriate guidelines for this finding at older ages.